A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man
- PMID: 2310654
- PMCID: PMC1380129
- DOI: 10.1111/j.1365-2125.1990.tb03639.x
A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man
Abstract
1. Twelve healthy extensive metabolisers of sparteine were sparteine tested daily for 6 days (19.00 h to 07.00 h). A small but statistically significant rise in sparteine metabolic ratio (MR) was observed. 2. Following 100 mg quinidine sulphate given to four of the subjects at 16.00 h, sparteine tests were carried out 19.00 h to 07.00 h on the same day and then daily for 6 days. Quinidine caused an immediate twenty-fold increase in sparteine-MR which then gradually returned to normal over the following 4-6 days. Quinidine concentrations in plasma were measurable only up to 20 h after the quinidine test dose. 3. At weekly intervals, all 12 subjects received single doses of quinidine sulphate of 5, 10, 20, 40 and 80 mg at 16.00 h, each time followed by a sparteine test 19.00 h to 07.00 h on the same day. A clear dose-effect relationship was found with a significant rise in the sparteine-MR even after 5 mg quinidine. After 80 mg quinidine, 8 of 12 subjects became phenotypically poor metabolisers (MR greater than 20).
Similar articles
-
Sparteine oxidation is practically abolished in quinidine-treated patients.Br J Clin Pharmacol. 1986 Aug;22(2):194-7. doi: 10.1111/j.1365-2125.1986.tb05250.x. Br J Clin Pharmacol. 1986. PMID: 3756067 Free PMC article.
-
Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.Br J Clin Pharmacol. 1990 Feb;29(2):248-53. doi: 10.1111/j.1365-2125.1990.tb03628.x. Br J Clin Pharmacol. 1990. PMID: 2306418 Free PMC article.
-
Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.Eur J Clin Pharmacol. 1995;48(6):501-4. doi: 10.1007/BF00194341. Eur J Clin Pharmacol. 1995. PMID: 8582470 Clinical Trial.
-
Substantial rise in sparteine metabolic ratio during haloperidol treatment.Br J Clin Pharmacol. 1989 Feb;27(2):272-5. doi: 10.1111/j.1365-2125.1989.tb05362.x. Br J Clin Pharmacol. 1989. PMID: 2713222 Free PMC article.
-
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.Eur J Clin Pharmacol. 1986;31(1):69-72. doi: 10.1007/BF00870989. Eur J Clin Pharmacol. 1986. PMID: 3780830
Cited by
-
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.Clin Pharmacokinet. 1996 Jul;31(1):9-28. doi: 10.2165/00003088-199631010-00002. Clin Pharmacokinet. 1996. PMID: 8827397 Review.
-
Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.Br J Clin Pharmacol. 2000 Feb;49(2):180-4. doi: 10.1046/j.1365-2125.2000.00120.x. Br J Clin Pharmacol. 2000. PMID: 10671914 Free PMC article. Clinical Trial.
-
Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.Br J Clin Pharmacol. 2003 Jul;56(1):57-67. doi: 10.1046/j.1365-2125.2003.01853.x. Br J Clin Pharmacol. 2003. PMID: 12848776 Free PMC article. Clinical Trial.
-
The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers.Eur J Clin Pharmacol. 1992;43(4):441-3. doi: 10.1007/BF02220625. Eur J Clin Pharmacol. 1992. PMID: 1451729 Clinical Trial.
-
Drug interactions with proton pump inhibitors.Drug Saf. 1997 Mar;16(3):171-9. doi: 10.2165/00002018-199716030-00003. Drug Saf. 1997. PMID: 9098655 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources